Amneal Pharmaceuticals Inc (NYSE:AMRX) has been given a consensus rating of “Hold” by the eleven analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $23.00.
A number of analysts recently weighed in on AMRX shares. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 price target on shares of Amneal Pharmaceuticals in a research note on Thursday, August 9th. Canaccord Genuity reiterated a “hold” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a research report on Tuesday, September 4th. Zacks Investment Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Saturday, July 14th. BMO Capital Markets boosted their target price on Amneal Pharmaceuticals from $19.00 to $20.00 and gave the stock a “market perform” rating in a research report on Friday, August 10th. Finally, ValuEngine downgraded Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 27th.
In other Amneal Pharmaceuticals news, CFO Bryan M. Reasons sold 11,698 shares of the business’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total transaction of $276,657.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Nikita Shah sold 50,000 shares of the business’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $23.46, for a total value of $1,173,000.00. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of AMRX. SG Americas Securities LLC purchased a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at $120,000. Neuburgh Advisers LLC purchased a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at $123,000. Great West Life Assurance Co. Can purchased a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at $130,000. Sei Investments Co. purchased a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at $139,000. Finally, Riverhead Capital Management LLC purchased a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at $141,000. Institutional investors own 32.39% of the company’s stock.
Amneal Pharmaceuticals stock opened at $18.97 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.25 and a debt-to-equity ratio of 2.85. Amneal Pharmaceuticals has a 1-year low of $13.47 and a 1-year high of $24.48. The company has a market capitalization of $5.51 billion, a P/E ratio of 30.11, a price-to-earnings-growth ratio of 0.87 and a beta of 1.56.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Thursday, August 9th. The company reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.01. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The firm had revenue of $462.33 million for the quarter, compared to the consensus estimate of $460.82 million. Amneal Pharmaceuticals’s revenue for the quarter was down 2.5% on a year-over-year basis. On average, equities analysts anticipate that Amneal Pharmaceuticals will post 0.94 earnings per share for the current fiscal year.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Further Reading: Why do company’s buyback their stock?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.